Theranexus SA

Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and TrophosMichele Garufi, former Chairman and CEO of Nicox, hands over his Board position after over more than 25 years at the company he co-foundedThe Nicox Board has now been entirely renewed to bring in the expertise to support the Company’s strategic direction going forward September 4th, 2024 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that Michele Garufi is stepping down as a member of the Board of Directors. The Board has appointed Christine Placet, a deeply experienced CEO and financial leader in the biotech industry, as a new Board member. The renewal of the Nicox Board brings the appropriate expertise to support the Company’s strategic direction going forward.“I am delighted to welcome Christine Placet to Nicox as a new Board member. I had the pleasure of working with Christine during our time at Trophos, where she played a pivotal role as CFO. Her expertise, strategic vision, and leadership in biotech are invaluable assets to Nicox. I look forward to working closely with her again as we continue to drive the business forward, with the focus on our de-risked compound NCX 470, moving towards topline results from the second pivotal Phase 3 trial, Denali, in H2 2025,” said Damian Marron, Chairman of Nicox.“On behalf of the Board and of Nicox, past and present, I would like to express my heartfelt gratitude to Michele Garufi for his dedicated and unstinting service to the company. Nicox has benefited from Michele’s vision, business acumen, scientific expertise and leadership for nearly 30 years, as we have sought to develop innovative solutions to help maintain vision and improve ocular health. We all wish Michele the very best for the future.” Michele Garufi, Co-Founder of Nicox, who served as CEO and Chairman until 2022 commented: “After many years of service at Nicox, this is the right time to hand over to a new generation of leadership. With Damian Marron appointed Chairman and Gavin Spencer as CEO earlier this year, we have a talented and dynamic leadership team in place who have led companies through critical phases of development and executed major financial transactions. I am therefore confident that Nicox is in very capable hands. I wish them every further success as they aim to deliver on the potential of NCX 470 to improve treatment of glaucoma.” Christine Placet joins Nicox with a distinguished career in the biotech industry. She started as an auditor at Ernst & Young and then built up extensive experience of financial leadership in small- and medium- sized companies. In 2004, she joined the biotech company Trophos as Chief Financial Officer, later becoming Chief Executive Officer. Under her leadership, Trophos was acquired by Roche for €470 million in 2015. She then became CEO of Horama (now Coave Therapeutics) in 2016, successfully leading funding rounds and advancing a key product into development. In 2021, she transitioned into consulting and joined Theranexus as CFO in April 2024. She is a graduate of Kedge Business School.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com Media / Investors Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.comDisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NewBoardMemberChristinePlacet_PR_FINAL

Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions, The FDA confirmed that this sole Phase III trial would secure Batten-1 approval for Batten CLN3 disease. LYON, FRANCE and AUSTIN, TX / ACCESSWIRE / May 9, 2023 / Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF), have today announced receipt of approval from the Food and Drug Administration (FDA) for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics (DRDMG) held in mid-April. " We are delighted with the constructive discussions we had with the FDA on defining the endpoints of Batten-1 and the design of our pivotal Phase III trial. Its valuable guidance allows us to get fully prepared for the trial launch," explained Theranexus' Chief Medical Officer Marie Sebille. " We would like to thank the FDA for its support, which is fundamental to the development of our Batten-1 drug candidate, the only asset in active clinical development for Batten disease (CLN3). Our pivotal Phase III trial will enable us to gain approval for Batten-1, and also deliver rich news flow throughout the duration of the Phase III trial thanks to the parallel open-label patient cohort. More generally, we have no doubt that we can deliver a therapeutic response for patients suffering from Batten disease," added Theranexus' CEO Mathieu Charvériat. Theranexus and BBDF worked with the FDA's DRDMG to define the following criteria for the protocol of the Phase III multicenter trial for evaluating Batten-1 in patients with juvenile Batten disease (CLN3): The trial will be a randomized, double-blind study conducted versus placebo in 2 parallel groups to assess the efficacy of Batten-1 at a dose of 15 mg/kg and up to 600 mg/day for a 2-year treatment period, The target population will be a pediatric cohort involving approximately 60 patients aged 4 to 16 years, with randomization stratified into 3 age groups of 4 to 8 years, 9 to 12 years and 13 to 16 years to achieve suitable representation for all age groups assessed, The primary endpoint will be visual acuity, measured using either the quantitative LogMAR[1] scale, or a qualitative scale in the most impaired patients for whom quantitative assessment is not possible, The secondary endpoints will include cognitive function, assessed by the Verbal Comprehension Index from the Wechsler Intelligence Scale for Children according to age, motor function assessed by a selection of motor items from the Unified Batten Disease Rating Scale (UBDRS), and visual function, assessed by OCT scan, An assessment of functional ability in everyday activities and a Quality-of-Life measurement will also be performed. An additional open-label cohort of 9 patients' representative of the different age groups of the target population will be enrolled in parallel. This will allow us to enrich the statistical analysis plan, in particular in comparison with natural history data, for the primary and secondary endpoints on trial completion, and produce interim results every 6 months, including measurements of biomarkers (notably glycosphingolipids given their toxic accumulation resulting in neuronal death) and efficacy data on the same criteria as the main 60-patient cohort. Patient enrollment should begin in the end of 2023. The trial will run in parallel in several centers throughout the United States and Europe. Provided positive results are registered, the FDA confirms that a sole Phase III trial as defined above would secure approval of the Batten-1 candidate in Batten disease. The company's goal is to use the results of this trial to win product approval in both the United States and Europe. As a reminder, the Phase III trial follows on from Phase I/II whose initial results showed good safety and tolerability of miglustat in a population of CLN3 patients over 17 years of age, and a pharmacokinetic pro line with expectations (see press release of 5 January 2023[2]). In conclusion, Craig Benson, Chair of the Beyond Batten Disease Foundation , said: "We are absolutely delighted to have had such a constructive and productive meeting with the FDA enabling us to initiate the Phase III clinical trial for Batten-1 in the near future. Patients and their families are eagerly awaiting the launch of enrollment for this trial in a disease for which there is currently no available treatment. This trial is a source of tremendous hope for them." About Batten-1 Batten-1 is a novel and exclusive proprietary drug containing the active ingredient miglustat. The mechanism of action of this substance blocks the accumulation of glycosphingolipids and neuroinflammation. For patients over 17 years of age in the Phase I/II trial, the product is administered in solid form. In the Phase III trial, it will be administered in a liquid form better suited to pediatric patients. Phase I/II trial design: this is an open-label trial involving 6 patients over 17 years of age with CLN3 Batten disease, treated with miglustat up to 600 mg/day for a 2-year period. The primary endpoint is patient safety and tolerability, assessed using reports of adverse effects, biological tests and ECG, as well as the pharmacokinetics of miglustat. The secondary endpoints include efficacy monitoring: Unified Batten Disease Rating Scale, visual acuity, and brain MRI and optical coherence tomography scans. Administration of Batten-1 in escalating doses with a maximum of 600 mg/day was well tolerated, with no severe side effects observed causing treatment discontinuation. The most commonly reported adverse events are reversible gastrointestinal effects of often light to moderate severity, thus demonstrating the good tolerability pro Batten-1 in this population. Batten-1 will continue to be assessed in these patients treated over a 24-month period. Further information about the trial is available on . About Batten disease Juvenile Batten disease, also known as Spielmeyer-Vogt or CLN3 disease, is a rare, fatal, inherited disorder of the nervous system for which there is no treatment or cure. Juvenile Batten disease belongs to a group of disorders referred to as neuronal ceroid lipofuscinoses (NCLs). Over 400 different errors in 13 genes have been attributed to various forms of NCL, which differ from one another primarily by when symptoms first appear. The first symptom in the juvenile form, progressive vision loss, appears between the ages of 4 and 6 which is followed by personality changes, behavioral problems, and slowed learning. Seizures commonly appear within 2-4 years of the onset of disease. Over time, patients continue to decline mentally and physically. Eventually, those affected become wheelchair-bound, are bedridden, and die prematurely. Psychiatric symptoms or psychosis can appear at any time. Juvenile Batten disease is always fatal; usually by the late teens to early 20s. In the United States and Europe, the juvenile form is the most common of the NCLs, which together, affect nearly 3,000 patients[3]. In pathophysiological terms, interactions between neurons and glial cells play key roles in the emergence and progression of all the NCLs. About Beyond Batten Disease Foundation Beyond Batten Disease Foundation (BBDF) is the world's largest nonprofit organization dedicated to funding research for a treatment and cure for juvenile (CLN3) Batten disease. Since its inception in 2008, over $35 million has been invested in research by leveraging donations, co-funding and strategic partnerships. BBDF is spearheading a unique, cohesive strategy, incorporating independent scientific resources and collaboration with related organizations to drive research in juvenile Batten Disease[4]. Today there is a treatment in sight. BBDF funded research has discovered a drug - Batten-1 - that slows the progression of the disease in Batten models. More information can be found at . About Theranexus Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX). More information at Click and follow us on Twitter and Linkedln Contacts THERANEXUS Thierry Lambert Chief Financial Officer contact@theranexus.com NEWCAP Théo Martin/Pierre Laurent Investor Relations +33 (0)1 44 71 94 97 theranexus@newcap.eu FP2COM Florence Portejoie Media Relations + 33 (0)6 07 76 82 83 fportejoie@fp2com.fr Disclaimer This press release contains certain forward-looking statements concerning Theranexus and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Theranexus considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Theranexus filed with the AMF on 27 April 2023 under number D.23-0345 (a copy of which is available on ) and to the development of economic conditions, financial markets and the markets in which Theranexus operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Theranexus or not currently considered material by Theranexus. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Theranexus to be materially different from such forward-looking statements. Theranexus expressly declines any obligation to update such forward-looking statements. [1] LogMAR is used to express visual acuity in order to perform statistical calculations such as mean, standard deviation for visual acuity, etc. [2] [3] National Organization for Rare Disorders (NORD)/Orphanet [4] Settembre et al, TFEB links autophagy to lysosomal biogenesis, Science 2011 SOURCE: Theranexus View source version on accesswire.com:

This press release updates an earlier issuance with updated language throughout. Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions, The FDA confirmed that this sole Phase III trial would secure Batten-1 approval for Batten CLN3 disease. LYON, FRANCE and AUSTIN, TX / ACCESSWIRE / May 9, 2023 / Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and the Beyond Batten Disease Foundation (BBDF), have today announced receipt of approval from the Food and Drug Administration (FDA) for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics (DRDMG) held in mid-April. "We are delighted with the constructive discussions we had with the FDA on defining the endpoints of Batten-1 and the design of our pivotal Phase III trial. Its valuable guidance allows us to get fully prepared for the trial launch," explained Theranexus' Chief Medical Officer Marie Sebille. "We would like to thank the FDA for its support, which is fundamental to the development of our Batten-1 drug candidate, the only asset in active clinical development for Batten disease (CLN3). Our pivotal Phase III trial will enable us to gain approval for Batten-1, and also deliver rich news flow throughout the duration of the Phase III trial thanks to the parallel open-label patient cohort. More generally, we have no doubt that we can deliver a therapeutic response for patients suffering from Batten disease," added Theranexus' CEO Mathieu Charvériat. Theranexus and BBDF worked with the FDA's DRDMG to define the following criteria for the protocol of the Phase III multicenter trial for evaluating Batten-1 in patients with juvenile Batten disease (CLN3): The trial will be a randomized, double-blind study conducted versus placebo in 2 parallel groups to assess the efficacy of Batten-1 at a dose of 15 mg/kg and up to 600 mg/day for a 2-year treatment period, The target population will be a pediatric cohort involving approximately 60 patients aged 4 to 16 years, with randomization stratified into 3 age groups of 4 to 8 years, 9 to 12 years and 13 to 16 years to achieve suitable representation for all age groups assessed, The primary endpoint will be visual acuity, measured using either the quantitative LogMAR1 scale, or a qualitative scale in the most impaired patients for whom quantitative assessment is not possible, The secondary endpoints will include cognitive function, assessed by the Verbal Comprehension Index from the Wechsler Intelligence Scale for Children according to age, motor function assessed by a selection of motor items from the Unified Batten Disease Rating Scale (UBDRS), and visual function, assessed by OCT scan, An assessment of functional ability in everyday activities and a Quality-of-Life measurement will also be performed. An additional open-label cohort of 9 patients representative of the different age groups of the target population will be enrolled in parallel. This will allow us to enrich the statistical analysis plan, in particular in comparison with natural history data, for the primary and secondary endpoints on trial completion, and produce interim results every 6 months, including measurements of biomarkers (notably, glycosphingolipids given their abnormal accumulation and role in neuronal death) and efficacy data on the same criteria as the main 60-patient cohort. Patient enrollment should begin by the end of 2023. The trial will run in parallel in several centers internationally, including the United States and Europe. Provided positive results are registered, the FDA confirms that a sole Phase III trial as defined above would secure approval of the Batten-1 candidate in CLN3 Batten disease. The company's goal is to use the results of this trial to win product approval in both the United States and Europe. As a reminder, the Phase III trial follows on from Phase I/II in which initial results showed good safety and tolerability of miglustat in a population of CLN3 patients over 17 years of age, and a pharmacokinetic pro line with expectations (see press release of 5 January 20232). In conclusion, Craig Benson, Chair of the Beyond Batten Disease Foundation , said: "We are absolutely delighted to have had such a constructive and productive meeting with the FDA enabling us to initiate the Phase III clinical trial for Batten-1 in the near future. Patients and their families are eagerly awaiting the launch of enrollment for this trial in a disease for which there is currently no available treatment. This trial is a source of tremendous hope for them." About Batten-1 Batten-1 is a novel and exclusive proprietary drug containing the active ingredient miglustat. The mechanism of action of this substance blocks the accumulation of glycosphingolipids and neuroinflammation. For patients over 17 years of age in the Phase I/II trial, the product is administered in solid form. In the Phase III trial, it will be administered in a liquid form better suited to pediatric patients. Phase I/II trial design: this is an open-label trial involving 6 patients over 17 years of age with CLN3 Batten disease, treated with miglustat up to 600 mg/day for a 2-year period. The primary endpoint is patient safety and tolerability, assessed using reports of adverse effects, biological tests and ECG, as well as the pharmacokinetics of miglustat. The secondary endpoints include efficacy monitoring: Unified Batten Disease Rating Scale, visual acuity, and brain MRI and optical coherence tomography scans. Administration of Batten-1 in escalating doses with a maximum of 600 mg/day was well tolerated, with no severe side effects observed causing treatment discontinuation. The most commonly reported adverse events are reversible gastrointestinal effects of often light to moderate severity, thus demonstrating the good tolerability pro Batten-1 in this population. Batten-1 will continue to be assessed in these patients treated over a 24-month period. Further information about the trial is available on . About Batten disease Juvenile Batten disease, also known as Spielmeyer-Vogt or CLN3 disease, is a rare, fatal, inherited disorder of the nervous system for which there is no treatment or cure. Juvenile Batten disease belongs to a group of disorders referred to as neuronal ceroid lipofuscinoses (NCLs). Over 400 different errors in 13 genes have been attributed to various forms of NCL, which differ from one another primarily by when symptoms first appear. The first symptom in the juvenile form, progressive vision loss, appears between the ages of 4 and 6 which is followed by personality changes, behavioral problems, and slowed learning. Seizures commonly appear within 2-4 years of the onset of disease. Over time, patients continue to decline mentally and physically. Eventually, those affected become wheelchair-bound, are bedridden, and die prematurely. Psychiatric symptoms or psychosis can appear at any time. Juvenile Batten disease is always fatal; usually by the late teens to early 20s. In the United States and Europe, the juvenile form is the most common of the NCLs, which together, affect nearly 3,000 patients3. In pathophysiological terms, interactions between neurons and glial cells play key roles in the emergence and progression of all the NCLs. About Beyond Batten Disease Foundation Beyond Batten Disease Foundation (BBDF) is the world's largest nonprofit organization dedicated to funding research for a treatment and cure for juvenile (CLN3) Batten disease. Since its inception in 2008, over $35 million has been invested in research by leveraging donations, co-funding and strategic partnerships. BBDF is spearheading a unique, cohesive strategy, incorporating independent scientific resources and collaboration with related organizations to drive research in juvenile Batten Disease4. Today there is a treatment in sight. BBDF funded research has discovered a drug - Batten-1 - that slows the progression of the disease in Batten models. More information can be found at . About Theranexus Theranexus is an innovative biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company has a unique platform for the identification and characterization of advanced therapy drug candidates targeting rare neurological disorders and an initial drug candidate in clinical development for Batten disease. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX). More information at Click and follow us on Twitter and Linkedln Contacts THERANEXUS Thierry Lambert Chief Financial Officer contact@theranexus.com NEWCAP Théo Martin/Pierre Laurent Investor Relations +33 (0)1 44 71 94 97 theranexus@newcap.eu FP2COM Florence Portejoie Media Relations + 33 (0)6 07 76 82 83 fportejoie@fp2com.fr Disclaimer This press release contains certain forward-looking statements concerning Theranexus and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Theranexus considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the universal registration document of Theranexus filed with the AMF on 27 April 2023 under number D.23-0345 (a copy of which is available on ) and to the development of economic conditions, financial markets and the markets in which Theranexus operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Theranexus or not currently considered material by Theranexus. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Theranexus to be materially different from such forward-looking statements. Theranexus expressly declines any obligation to update such forward-looking statements. 1 LogMAR is used to express visual acuity in order to perform statistical calculations such as mean, standard deviation for visual acuity, etc. 2 3 National Organization for Rare Disorders (NORD)/Orphanet 4 Settembre et al, TFEB links autophagy to lysosomal biogenesis, Science 2011 SOURCE: Theranexus View source version on accesswire.com: